Document is current

Article History

Accepted: 10 November 2022

First Online: 14 December 2022

Declarations

:

: RS has received research support from Janssen, GSK and Takeda. DA has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and serves as a paid consultant for H. Lundbeck and Axovant. CB has received honoraria and grant funding from Acadia Pharmaceuticals, Lundbeck, Takeda and Axovant pharmaceutical companies. CB leads the Alzheimer’s disease psychosis (ADP) investigators group and has received honoraria from Lundbeck, Lilly, Otusaka and Orion pharmaceutical companies. MR, MT, BC, LV, KT and CM declare no conflicts of interest.

: CM, DA and RS receive salary support from the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, and RS is a NIHR Senior Investigator. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: MR: Review of literature, interpretation of data, preparation of the manuscript, and critical revision for intellectual content. CM: Article concept and design, interpretation of data, and critical revision of the manuscript for intellectual content. BC, LV, DA, CB, KT, RS: Interpretation of data and critical revision of the manuscript for intellectual content. MT: Critical revision for intellectual content, preparation of the manuscript. All authors approved the manuscript to be published and agree to be accountable for all aspects of the work.